Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
收藏数据链接：
官方服务：
资源简介：
TRAEs (reported as PTs) in ≥20% of patients, grade ≥3 TRAEs in ≥5% of patients, and AESIs in ≥10% of patients in the dose-expansion phase.
创建时间：
2025-11-26
